AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments

3 June 2013

Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory firm Decision Resources, US drugmaker AbbVie (NYSE: ABBV) and Japan’s Eisai's (TYO: 4523) Humira (adalimumab) has the strongest clinical profile among key marketed products that treat psoriatic arthritis (PsA).

None of the PsA therapies in development show advantages in efficacy over Humira, although UCB (Euronext Brussels: UCB) and Astellas' (TYO: 4503) Cimzia (certolizumab pegol) has a clinical profile that is not differentiated from Humira based on thought leader opinion and clinical trial data.

According to the DecisionBase 2013 report titled Opportunity Remains for Novel Therapies That Address Rheumatologists' and Payers' Shared Views on Unmet Need in the TNF-Alpha-Inhibitor-Dominated PsA Market, while some other therapies in development hold promise, they have efficacy, safety and tolerability, and/or delivery disadvantages compared with Humira and Cimzia. Humira has been forecast as achieving sales of $10 billion this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK